Home » Pipeline
Pipeline
March 11, 2019
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| AOBiome Therapeutics, Inc. | B244 | pediatric patients with atopic dermatitis (eczema) | Phase Ib trial initiated enrolling 36 subjects aged 2 to 17 years |
| Forbius | AVID200 | diffuse cutaneous systemic sclerosis (SSc) | Phase Ib trial initiated |
| I-Mab Biopharma | TJ107 (HyLeukin) | advanced solid tumors | Phase Ib/IIa trial initiated enrolling 58 subjects in China |
| Odonate Therapeutics, Inc. | tesetaxel | locally advanced or metastatic breast cancer (LA/MBC) | Phase II trial initiated enrolling 125 subjects with human epidermal growth factor receptor 2 (HER2) negative, hormone receptor (HR) positive disease who have not previously received a taxane |
| Eidos Therapeutics, Inc. | AG10 | transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) | Phase III trial initiated enrolling 510 subjects with symptomatic ATTR-CM, associated with either wild-type or mutant TTR, with New York Heart Association Class I-III symptoms |
| Inovio | VGX-3100 | cervical dysplasia caused by human papillomavirus (HPV) | Phase III trial initiated enrolling adult female subjects with HPV 16/18 positive biopsy-proven cervical HSIL, otherwise known as cervical intraepithelial neoplasia (CIN) 2 or 3 |
| Acceleron Pharma, Inc. | ACE-083 | Charcot-Marie-Tooth disease (CMT) | Orphan Drug designation granted by the FDA |
| Mitochon Pharmaceuticals | MP-101 | Huntington’s Disease | Orphan Drug designation granted by the FDA |
| Celgene Corporation | fedratinib | myelofibrosis | Priority Review granted by the FDA |
| NKMax America | SNK01 | refractory cancer | IND approval granted by the FDA |
| Breckenridge Pharmaceutical, Inc. | Imatinib Mesylate Tablets | cancer | ANDA approval granted by the FDA |
| Janssen | Spravato | major depressive disorder | Approval granted by the FDA |
| Baxter International, Inc. | eptifibatide | acute coronary syndrome (ACS) | Approval granted by the FDA |
| Adlon Therapeutics, L.P.m | Adhansia XR (methylpheni-date hydrochloride) extended-release capsules CII | Attention-Deficit/Hyperactivity Disorder (ADHD) | Approval granted by the FDA |
